(UroToday.com) In this presentation, Dr. Maria DeSantis reviewed the history of STAMPEDE for context on the data presented in abstract 611O for long term follow-up on outcomes in men with metastatic hormone-sensitive prostate cancer randomized to either standard of care or standard of care plus abiraterone acetate. She first focused on the results of the long-term follow-up, then discussed how these data have been implemented in the real world, then ended with a discussion of how clinical and molecular features may impact treatment selection amongst the multiple agents with efficacy as first-line therapy in metastatic hormone-sensitive prostate cancer.